94 related articles for article (PubMed ID: 15966995)
1. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study.
Pajek J; Bucar-Pajek M; Grego K; Gucek A; Bevc S; Ekart R; Vujkovac B; Golob-Kosmina P; Kandus A; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):228-32. PubMed ID: 15966995
[TBL] [Abstract][Full Text] [Related]
2. Inflammation, peritoneal transport, and response to erythropoietin in peritoneal dialysis patients.
Pilkey RM; Morton AR; Iliescu EA
Adv Perit Dial; 2001; 17():153-7. PubMed ID: 11510266
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
4. Our experience with epoetins in treating renal anemia.
Bren A; Kandus A
Ther Apher Dial; 2005 Jun; 9(3):202-4. PubMed ID: 15966988
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
6. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J; Gassmann-Mayer C; Frei D; McClellan W
Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
Malovrh M; Premru V
Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
[TBL] [Abstract][Full Text] [Related]
12. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
13. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value].
Wallerstedt SM; Ljungman S; Broms E; Andrén L
Lakartidningen; 2005 Sep 12-18; 102(37):2550-1, 2553-5. PubMed ID: 16200900
[TBL] [Abstract][Full Text] [Related]
14. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
Drüeke TB; Locatelli F; Clyne N; Eckardt KU; Macdougall IC; Tsakiris D; Burger HU; Scherhag A;
N Engl J Med; 2006 Nov; 355(20):2071-84. PubMed ID: 17108342
[TBL] [Abstract][Full Text] [Related]
15. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
Linde T; Furuland H; Wikström B
Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
[TBL] [Abstract][Full Text] [Related]
16. Diabetic patients on peritoneal dialysis need less erythropoietin to maintain adequate hemoglobin.
Pagé DE; Cheung V; Poirier F
Adv Perit Dial; 2001; 17():130-1. PubMed ID: 11510260
[TBL] [Abstract][Full Text] [Related]
17. Anaemia in patients with chronic kidney disease: management with epoetin beta in primary care setting in New Zealand.
Madhan KK; Chamberlain M; Anderson E
Nephrology (Carlton); 2008 Oct; 13(5):428-32. PubMed ID: 18331435
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
19. Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis.
Pérez-Flores I; Coronel F; Cigarrán S; Herrero JA; Calvo N
Adv Perit Dial; 2007; 23():140-3. PubMed ID: 17886621
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.
Navarro JF; Macía ML; Mora-Fernández C; Gallego E; Chahin J; Méndez ML; del Castillo N; Rivero A; García J
Adv Perit Dial; 1997; 13():257-9. PubMed ID: 9360694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
